These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38932620)

  • 1. Are ketamine and its enantiomers the answer to treatment-refractory depression?
    Belge JB; Scantamburlo G; Constant E
    Expert Rev Neurother; 2024 Sep; 24(9):827-830. PubMed ID: 38932620
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ketamine--a new treatment option for therapy-resistant depression].
    Köhler S; Betzler F
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine for treatment-resistant depression: ready or not for clinical use?
    Rush AJ
    Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine for Major Depressive Disorder.
    Costi S
    Curr Top Behav Neurosci; 2024; 66():131-147. PubMed ID: 37922100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A word to the wise about ketamine.
    Schatzberg AF
    Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
    [No Abstract]   [Full Text] [Related]  

  • 8. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
    Kellner CH; Greenberg RM; Ahle GM; Liebman LS
    Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
    [No Abstract]   [Full Text] [Related]  

  • 9. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 10. Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.
    Bartova L; Weidenauer A; Dold M; Naderi-Heiden A; Kasper S; Willeit M; Praschak-Rieder N
    J ECT; 2017 Sep; 33(3):e31-e32. PubMed ID: 28520578
    [No Abstract]   [Full Text] [Related]  

  • 11. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine: The final frontier or another depressing end?
    Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
    Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 15. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine: A Paradigm Shift for Depression Research and Treatment.
    Krystal JH; Abdallah CG; Sanacora G; Charney DS; Duman RS
    Neuron; 2019 Mar; 101(5):774-778. PubMed ID: 30844397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Intravenous Ketamine Better Than Intranasal Esketamine for Treating Treatment-Resistant Depression?
    Mansuri Z; Shah B; Yadav G; Kamil SH; Kainth T; Srinivas S; Patel H; Reddy A; Bachu A
    Prim Care Companion CNS Disord; 2024 Feb; 26(1):. PubMed ID: 38382071
    [No Abstract]   [Full Text] [Related]  

  • 18. Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression.
    Pérez-Esparza R; Corona T; Ruiz-García RG; Oñate-Cadena N; de la Fuente-Sandoval C; Ramírez-Bermúdez J
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):623. PubMed ID: 29744959
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
    Rotroff DM; Corum DG; Motsinger-Reif A; Fiehn O; Bottrel N; Drevets WC; Singh J; Salvadore G; Kaddurah-Daouk R
    Transl Psychiatry; 2016 Sep; 6(9):e894. PubMed ID: 27648916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine and the potential role for rapid-acting antidepressant medications.
    Krystal JH
    Swiss Med Wkly; 2007 Apr; 137(15-16):215-6. PubMed ID: 17525875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.